DMT
Uber to Shut Down Drizly Three Years After Acquisition
Uber (NYSE: UBER) is set to shut down its alcohol delivery app, Drizly, marking the end of a three-year journey
The post Uber to Shut Down Drizly Three…
Uber (NYSE: UBER) is set to shut down its alcohol delivery app, Drizly, marking the end of a three-year journey since the ride-sharing giant acquired the platform for $1.1 billion, according to Axios.
Drizly, which boomed with the pandemic era demand for at-home delivery, had become the largest online alcohol marketplace in North America. The closure is part of Uber’s strategic decision to streamline its offerings into the core Uber Eats platform.
Effective March 31, 2024, Drizly will cease operations as an independent app, and its marketplace will be seamlessly integrated into Uber Eats.
In a statement, Pierre Dimitri Gore-Coty, Uber’s senior vice president of delivery, emphasized the company’s commitment to focusing on the core Uber Eats strategy, aiming to provide consumers with a one-stop-shop for food, groceries, and alcohol.
“We’re grateful to the Drizly team for their many contributions to the growth of the BevAlc delivery category as the original industry pioneer,” Gore-Coty added.
Uber’s move to consolidate its delivery services also led to the discontinuation of the grocery shopping app, Cornershop.
Information for this story was found via Axios, and the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
The post Uber to Shut Down Drizly Three Years After Acquisition appeared first on the deep dive.
dimitri research-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics5 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment